Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01480726
Other study ID # N20110023
Secondary ID
Status Completed
Phase N/A
First received November 24, 2011
Last updated April 13, 2015
Start date November 2011
Est. completion date January 2015

Study information

Verified date November 2011
Source Aalborg Universitetshospital
Contact n/a
Is FDA regulated No
Health authority Denmark: National Board of Health
Study type Observational

Clinical Trial Summary

Vena saphena magna is still frequently used as graft material in coronary artery bypass grating(CABG, and vein grafts can harvest with either the conventional open technique (Ovh = open vein harvesting), or with less invasive endoscopic techniques (EVH = Endoscopic vein harvesting). The endoscopic techniques have been shown to reduce the incidence of postoperative wound complications while patients are more satisfied with the cosmetic result of the operation on the leg.

Non-randomized studies have raised doubts about patency rates of the vein grafts following EVH compared to OVH, while other studies failed to detect any problems in relation to this. There are only very few data on long-term patency rates from randomized studies.

The purpose of this study is to investigate clinical outcome and patency rates of the vein grafts following either EVH and OVH in 132 patients who underwent CABG for 4-7 years ago as part of a randomized study investigation wound complications. A cost-effectiveness analysis will also be performed.

The hypothesis is: Patency rates following EVH are worse compared to OVH in CABG 4-7 years postoperatively.


Description:

Background

Vena saphena magna is frequently used as graft material in coronary artery bypass grafting (CABG. Vein grafts can be harvested with conventional open technique (OVH = open vein harvesting), or with various endoscopic less invasive techniques (EVH = Endoscopic vein harvesting). The endoscopic techniques have been shown to reduce the incidence of postoperative wound complications and patients are more satisfied with the cosmetic surgery results.

Non-randomized trials, however, cast doubt on the patency rates of the vein grafts following EVH compared to OVH, while other studies including one randomized trial failed to detect any problems regarding this. There are no data regarding long-term patency rate following EVH.

It is therefore valuable to conduct a secondary follow-up among CABG patients who 4-7 years ago were included in a randomized trial focusing on wound complications from the leg. Although the study was not designed to evaluate the clinical results and patency rates of vein graft, such a study may still contribute with important knowledge because the results will come from a randomized patient cohorts, in contrast to results from most other studies.

Purpose

To investigate long-term patency rates (4-7 years) patency rates and clinical outcomes following EVH and OVH in first-time CABG.

We also want to perform a health economic analysis (cost-effectiveness analysis) to assess which of the two harvesting methods.

Hypotheses:

1. Patency rates following EVH are worse compared to OVH in CABG 4-7 years postoperatively.

2. EVH is associated with an increased incidence of recurrence of angina and the need for re-revascularization compared with OVH.

3. Although EVH immediately leads to higher direct costs compared with OVH, there is a health economic benefit of this method in the long run.

Methods:

This experiment consists of a follow-up among 129 of 132 former patients who underwent first-time CABG between April 2004 - June 2007 at Aalborg Hospital, Aarhus University Hospital, Denmark, comparing EVH and OVH. Register data will be collected and patient records will be reviewed. Surviving patients will be invited for a clinical evaluation. CT-angio in order to compare long-term patency rates of the vein grafts will be performed. Furthermore the incidence of recurrent angina, acute coronary syndrome, need for re-revascularization and cardiovascular death since the operation wil be evaluated.

All direct and indirect costs of the two methods of surgery and throughout the postoperative course until this study will be valued in order to perform a health economic analysis (cost-effectiveness analysis).

Subjects The age of the previous trial subjects was 65 years (range 43-90 years, at the time they were included in the previous study, and survivors will be 4-7 years old today.

It is expected that most of the surviving former patients will participate in the study.

Inclusion Criteria

All 129 former patients who were included in the initial trial may be included. Deceased patients are only included in the trial regarding registry data and medical records.

Exclusion criteria (in relation to the clinical examination):

Lack of consent. (Register Data for previous patients who did not give their informed consent for a clinical follow-up may be included in the study)

Exclusion criteria (in relation to CT-angio):

Former patients with at least one of the following exclusion criteria will not have a CT-angio performed:

p-creatinine> 120 micromol / l Estimated GFR (eGFR = estimated glomerular filtration rate) per 1.73 m2 <60 ml / min.

Atrial fibrillation Allergy to contrast media Pregnancy Breastfeeding Lack of consent


Recruitment information / eligibility

Status Completed
Enrollment 132
Est. completion date January 2015
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 43 Years to 90 Years
Eligibility Inclusion Criteria:

- Patients who participated in the previous randomized study

- Informed consent from the patient

Exclusion Criteria:

- Survival until date of reexamination

- No informed consent

- CT scan of the heart will not be performed in patients with if: atrial fibrillation,p-creatinin >120 micromol/l, allergy to contrast, pregnancy, lactating.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
Surgery


Locations

Country Name City State
Denmark Aalborg University Hospital Aalborg

Sponsors (2)

Lead Sponsor Collaborator
Aalborg Universitetshospital Aalborg University

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patency rates of vein grafts 5-7 years postoperatively No
Secondary recurrence of angina pectoris 5-7 years postoperatively No
See also
  Status Clinical Trial Phase
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting NCT02773615 - CT Perfusion Added to CT Angiography
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Terminated NCT02548611 - Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention Phase 4
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01425359 - Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina Phase 4
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
Completed NCT01604486 - Natural Ischaemic Preconditioning Before First Myocardial Infarction N/A
Completed NCT00811772 - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis N/A
Completed NCT00131183 - Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Phase 4
Completed NCT00184444 - Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients N/A
Completed NCT00235404 - Randomized Controlled Trial of Health Care to Elderly Patients. N/A
Terminated NCT00157742 - Comparison of SCS and PMR in Patients With Refractory Angina Pectoris Phase 4
Completed NCT00000510 - Platelet-Inhibitor Drug Trial in Coronary Angioplasty Phase 3
Completed NCT00005148 - Coronary Heart Disease Incidence, Mortality, and Risk Factor Relationships N/A
Not yet recruiting NCT03657758 - Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO] Phase 4
Completed NCT05050773 - Registry Study of Medical Therapy in Patients With Angina Pectoris(GREAT)
Completed NCT00093223 - A Safety Study of ABI-007 for In-Stent Restenosis Phase 2
Active, not recruiting NCT02508714 - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents N/A